*Some patients had more than 1 AE and may have been counted more than once.
When mild and unrelated AEs were excluded, the most commonly reported AEs with Xenazine compared to placebo were sedation/somnolence (31% vs 3%), fatigue (22% vs 13%), insomnia (22% vs 0%), depression (19% vs 0%), akathisia (19% vs 0%), anxiety (15% vs 3%), and nausea (13% vs 7%). One patient committed suicide.
If AEs such as akathisia, restlessness, parkinsonism, agitation, depression, insomnia, fatigue, anxiety or sedation/somnolence occur, titration should be stopped and the dose should be reduced.
If the adverse event does not resolve, consideration should be given to withdrawing Xenazine treatment or initiating other specific treatment (e.g. antidepressants).
XENAZINE® (tetrabenazine) Tablets
Indications and Usage:
XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease.
Important Safety Information:
For more information, please see the full Prescribing Information, including Boxed Warning, the Medication Guide or go to www.XENAZINEusa.com.
Xenazine is a registered trademark of Valeant International Bermuda or its affiliates.
©2017 Lundbeck, Deerfield, IL 60015. All rights reserved.
The product information provided in this site is intended only for residents of the U.S. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider.